77 results on '"Yoneshima, Yasuto"'
Search Results
2. Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review
3. TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer
4. Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis
5. A Case of Obstructing Bronchial Aspergillosis in a Patient Receiving Cytotoxic Chemotherapy and Inhaled Corticoid Therapy
6. Successful Treatment against Mediastinal Methicillin-resistant Staphylococcus aureus Infection after an Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Procedure
7. YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells
8. Osimertinib readministration for central nervous system metastases in non–small cell lung cancer positive for EGFR activating mutations
9. Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)
10. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase
11. MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma
12. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
13. Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β
14. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
15. Abstract 2173: A multi-institutional prospective biomarker study of durvalumab after concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer (WJOG11518L/SUBMARINE)
16. Carboplatin and Irinotecan (CI) vs. Carboplatin and Etoposide (CE) for the Treatment of Extended-Stage Small-Cell Lung Cancer in an Elderly Population: A Phase II/III Randomized Control Trial
17. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
18. Afatinib-Induced Bronchiolitis Obliterans
19. A Case of Obstructing Bronchial Aspergillosis in a Patient Receiving Cytotoxic Chemotherapy and Inhaled Corticoid Therapy
20. Pleuroparenchymal fibroelastosis secondary to autologous peripheral blood stem cell transplantation: A case report
21. Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers
22. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma
23. MicroRNA-326 Negatively Regulates CD155 Expression in Lung Adenocarcinoma
24. Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer
25. Nab-Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment
26. Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
27. P29-1 LIGHT-NING: An observational study of nivolumab plus ipilimumab with or without chemotherapy for 1st line NSCLC in Japan
28. Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)
29. A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
30. Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone
31. Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC
32. Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib
33. Abstract 1918: Coxsackievirus A11 elicits a potent oncolytic activity in human malignant pleural mesothelioma via ICAM-1 receptor
34. Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis
35. Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer
36. Albumin-bilirubin grade as a significant prognostic factor in patients with non-small cell lung cancer treated with anti-PD-1-based therapy: A multicenter retrospective study.
37. Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non–small cell lung cancer
38. Clinical impact of probiotics on the efficacy of anti‐PD ‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
39. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors
40. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors
41. Neural stem cell–specific ITPA deficiency causes neural depolarization and epilepsy
42. Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients
43. NEUROD1 is highly expressed in extensive disease small cell lung cancer by promoting migration
44. Association of Mps one binder kinase activator 1 ( MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
45. Abstract 2412: Pemetrexed induces calreticulin expression most robustly in parallel with apoptosis among chemotherapeutic agents used in non-small cell lung cancer (NSCLC) treatment
46. Abstract 4922: NEUROD1 is highly expressed in extensive small cell lung cancer by promoting migration
47. NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration
48. Pleuropulmonary Paragonimiasis with Multiple Nodules in the Pleura
49. HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors
50. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.